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INTRODUCTION
Despite the latest advances in anesthesia and the introduc-
tion of a new class of antiemetics, postoperative nausea and
vomiting (PONV) is still one of the most common postop-
erative patient complaints. Generally, one-third of patients
undergoing surgery are known to suffer from postoperative
nausea, vomiting, or both, and often rate PONV as worse
than postoperative pain (1). In addition, PONV, although
being not common but serious in its nature, has been asso-
ciated with various complications ranging from minor inci-
sional pain to more severe hematoma, wound dehiscence,
esophageal rupture, bilateral pneumothorax, and increased
risk for aspiration. Furthermore, discharge from the postanes-
thesia care unit (PACU) may be delayed, and hospital admis-
sion (or readmission) in ambulatory patients often occurs
due to PONV, which increases the overall medical cost (2). 
Numerous antiemetic regimens, alone or in combination,
have been used for treatment and tried for prophylaxis with
some degree of effectiveness. However, routine prophylaxis
is not recommended to all surgical patients because it may
impose unnecessary side effects as well as increase the overall
cost (3). Instead, selective prophylaxis in patients who are
likely to have PONV, after identifying the most predictive
risk factors, would offer much benefit resulting in improved
satisfaction (4). Several studies have been carried out to iden-
tify the risk factors for PONV and develop risk models to
calculate the probability of PONV (5, 6). Recently, the major
predictive risk factors for PONV were identified through a
large-scaled study in Korean population, and the Korean pre-
dictive model for PONV was developed. The following five
risk factors in the order of relevance were reported to be strong-
ly predictive of PONV: 1) female, 2) history of previous PO-
NV or motion sickness, 3) duration of anesthesia more than
1 hr, 4) non-smoking status, and 5) use of opioids in the form
of patient controlled analgesia (PCA). If none, one, two, three,
four, or five of these risk factors were present, the reported
incidence of PONV was 12.7%, 19.9%, 29.3%, 40.7%, 53.1
%, and 65.4%, respectively. The formula to calculate the
probability of PONV using the multiple regression analysis
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Combination of Antiemetics for the Prevention of Postoperative 
Nausea and Vomiting in High-Risk Patients 
It was previously reported that the Korean predictive model could be used to iden-
tify patients at high risk of postoperative nausea and vomiting (PONV). This study
investigated whether PONV in the high-risk and very high-risk patients identified
by the Korean predictive model could be prevented by multiple prophylactic antie-
metics. A total of 2,456 patients were selected from our previous PONV study and
assigned to the control group, and 374 new patients were recruited consecutively
to the treatment group. Patients in each group were subdivided into two risk groups
according to the Korean predictive model: high-risk group and very high-risk group.
Patients in the treatment group received an antiemetic combination of dexametha-
sone 5 mg (minutes after induction) and ondansetron 4 mg (30 min before the end
of surgery). The incidences of PONV were examined at two hours after the surgery
in the postanesthetic care unit and, additionally, at 24 hr after the surgery in the
ward, and were analyzed for any differences between the control and treatment
groups. The overall incidence of PONV decreased significantly from 52.1% to
23.0% (p≤ ≤0.001) after antiemetic prophylaxis. Specifically, the incidence decreas-
ed from 47.3% to 19.4% (p≤ ≤0.001) in the high-risk group and from 61.3% to 28.3%
(p≤ ≤0.001) in the very high-risk group. Both groups showed a similar degree of rel-
ative risk reductions: 59.0% vs. 53.8% in the high-risk and very high-risk groups,
respectively. The results of our study showed that the antiemetic prophylaxis with
the combination of dexamethasone and ondansetron was effective in reducing the
occurrence of PONV in both high-risk and very high-risk patients.
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was as follows: P (probability of PONV)=1/1+e-Z, Z=-1.885
+0.894 (gender)+0.661 (history)+0.584 (duration of anes-
thesia)+0.196 (smoking status)+0.186 (use of PCA-based
opioid) where gender: female=1, male=0; history of previous
PONV or motion sickness: yes=1, no=0; duration of anes-
thesia: more than 1 hr=1, less than or 1 hr=0; smoking sta-
tus: no=1, yes=0; use of PCA-based opioid: yes=1, no=0.
This model can be used to calculate the probability of PONV
in order to administer prophylactic antiemetics in selected
high-risk patients (7).
The most commonly studied combination of antiemetics
is a 5-HT3 receptor antagonist with either droperidol or dex-
amethasone with a similar degree of protective effects (8-
11). However, the Food and Drug Administration (FDA) has
limited the use of droperidol because of its potential associa-
tion with arrhythmia (12). Therefore, the most effective and
safest combination regimen seems to be the one with 5-HT3
antagonist and dexamethasone. Ondansetron is known to
have greater anti-vomiting than anti-nausea effects whereas
dexamethasone has a stronger anti-nausea effect (2, 11). The
aim of this study was to examine the prophylactic effect of
combined ondansetron and dexamethasone with complemen-
tary superiority in anti-vomiting and anti-nausea effects,
respectively, on the incidence of PONV in high-risk and very
high-risk patients based on the Korean predictive model.
MATERIALS AND METHODS
The Institutional Review Board approved this study, and
all patients provided written informed consent. We recruit-
ed 2,456 patients as the control group from our previous pre-
dictive study (7). The combinations of strong predictive risk
factors of PONV and the number of patients within each
combination were ranked from highest to lowest according
to the incidences of PONV. Next, we arbitrarily categorized
this list into four groups, low or mild (<20%), moderate
(20-40%), high (40-60%), and very high (>60%), and then
selected a number of more commonly occurring combina-
tions as reflected by the largest number of patients from
high-risk and very high-risk groups. As a result, 1,623 pa-
tients were of high-risk, who were nonsmoking females
without a history of PONV or motion sickness and their
operations were longer than 1 hr with the postoperative
opioid use not being counted. And 833 were very high-risk
patients, nonsmoking females with a history of PONV or
motion sickness with the other factors being the same. As
the treatment group, 374 patients were consecutively enroll-
ed in high-risk or very high-risk patients after identifying
the same risk factors as the control groups, and they received
intravenous injections of dexamethasone 5 mg, immediate-
ly after the induction of anesthesia and ondansetron 4 mg,
30 min before the end of surgery.
Anesthesia was induced intravenously using either thiopen-
tal (5 mg/kg) or propofol (2 mg/kg). Tracheal intubation was
facilitated with neuromuscular blocking agents (vecuronium,
0.15 mg/kg or rocuronium, 0.8 mg/kg), which were repeat-
ed according to clinical needs. For maintenance, all patients
received a balanced anesthetic technique with either volatile
anesthetics (sevoflurane, enflurane, isoflurane, or desflurane;
end tidal concentration 1-2 vol%) or propofol (50-200  g/
kg/min). Intraoperative opioids including fentanyl (2  g/kg),
morphine (0.1 mg/kg), or meperidine (0.5 mg/kg) were used
in some patients. Nitrous oxide was used at the anesthesiol-
ogist’s discretion. At the end of anesthesia, the patient’s neu-
romuscular block was reversed with a combination of pyri-
dostigmine 0.2 mg/kg and glycopyrrolate 0.005 mg/kg upon
the presence of four twitches under train-of-four stimulation.
The exclusion criteria included the administration of ste-
roid, prior history of gastrointestinal disease, diabetics, patients
transferred to ICU after surgery, and patients who were not
able to communicate within 24 hr after surgery. An intervie-
wer, who was blinded to the history of medication, assessed
and examined the presence and severity of PONV at 2 and
24 hr after the surgery in the PACU and in the ward, respec-
tively. Chlorpheniramine 4 mg was administered intrave-
nously if the patient complained of PONV in the ward. Each
patient was regarded as having PONV when she experi-
enced any nausea and/or vomiting within the first 24 post-
operative periods.
Prospective power analysis showed that to detect more than
50% decrease in the incidence of PONV in both high-risk
group and very high-risk group due to the treatment, 1,623
and 222 high-risk patients and 833 and 152 very high-risk
patients in control and treatment groups, respectively, would
give more than 90% power with a significance level of 0.05.
This is based on the data from our previous study that with-
out the treatment, the incidences of PONV in high-risk and
very high-risk groups are 47.4% and 61.3%, respectively.
A t-test was used to analyze the mean age and weight, and
a Mann-Whitney test was used to analyze the duration of
operation. A chi-square test was used to examine the PCA
and intraoperative opioid uses, anesthetic agent, and the inci-
dence of PONV. The effect of antiemetics in each group in
comparison to the previous study is presented as RRR (Rel-
ative Risk Reduction). A p<0.05 was considered significant.
RESULTS
There were no differences between the high-risk and very
high-risk groups of treatment and control groups with respect
to age, weight, PCA use, duration of operation, anesthetic
agent, and intraoperative opioid use (Table 1).
The overall incidence of PONV was significantly lower
(p<0.05) in the treatment group (86 of total 374 patients,
23.0%) than in the control group (1,279 of total 2,456 pati-
ents, 52.1%) (Table 2). 880 E.J. Kim, J.S. Ko, C.S. Kim, et al.
In the high-risk groups, 43 of 222 (19.4%) patients in the
treatment group and 768 of 1,623 (47.3%) patients in the
control group complained of PONV, and the incidence of
PONV was significantly lower in the treatment group (p<
0.05). In the very high-risk groups, 43 of 152 (28.3%) pa-
tients in the treatment group and 511 of 833 (61.3%) pa-
tients in the control group developed PONV. Likewise, the
incidence of PONV was significantly lower in the treatment
group (p<0.05). However, there was no significant difference
between the two groups with respect to RRR: 59.0% in
the high-risk group and 53.8% in the very high-risk group
(Table 2). 
The incidences of nausea in the control and treatment groups
were 48.3% (1187 patients) and 22.2% (83 patients), respec-
tively. There was a significantly greater anti-nausea effect in
the treatment group (p<0.05). Vomiting was observed in
12.6% (309 patients) and 4.0% (15 patients) in the control
and the treatment groups, respectively. The incidence of vom-
iting was significantly reduced in the treatment group
compared to the control group, but only a minor antiemetic
effect was observed (Table 3).
DISCUSSION
The data of our study clearly demonstrated that prophy-
lactic administration of combined ondansetron and dexam-
ethasone in the selective groups of high-risk and very high-
risk patients was highly effective in decreasing the incidences
of PONV from 47.4% and 61.3% to 19.4% and 28.3%,
respectively. 
It is now generally accepted that PONV is one of the most
distressing side effects after anesthesia, with an incidence up to
70% of ‘‘high-risk’’ inpatients during the 24 hr postoperative
period. The well established risk factors of PONV are female
gender post-puberty, nonsmoking status, history of PONV
or motion sickness, childhood after infancy and younger adult-
hood, increasing duration of surgery, use of volatile anesthet-
ics, nitrous oxide, large-dose neostigmine, and intraoperative
or postoperative opioids (13). In accordance to above findings,
our previous study identified five very similar risk factors:
1) female, 2) history of previous PONV or motion sickness,
3) duration of anesthesia more than 1 hr, 4) non-smoking sta-
tus, and 5) use of opioid in the form of patient controlled
analgesia (PCA), in the order of relevance (7). 
The etiologies of PONV have been identified to be multi-
Control group (n=2,465)
G1 G2
Treatment group (n=374)
G1 G2
Number of patients 1,623 833 222 152
Age (yr) 48.2±15.2 48.4±15.4 45.1±12.8 45.5±12.7
Weight (kg) 62.1±11.3 63.2±11.5 58.1±8.2 59.9±8.7
PCA use (n) 664 (40.9%) 358 (43.0%) 91 (41.0%) 69 (45.4%)
Duration of operation (min) 115.0±79.0 117.0±72.3 148.0±79.5 125.0±61.5
Anesthetic agent: Volatile 1,602 (98.7%) 828 (99.4%) 222 (100%) 152 (100%)
Propofol 21 (1.3%) 5 (0.6%) 0 0
Intra-OP opioid 1,457 (89.8%) 769 (92.3%) 206 (92.8%) 137 (90.1%)
Table 1. Demographic data of study patients
G 1, High-risk group; G 2, Very high-risk group; PCA, patient-controlled analgesia; Intra-OP, intra-operation.
Values are expressed as Mean±SD. Data are number (%) of patients.
Control group
(n=2,465)
Treatment group
(n=374)
OR 95% CI RRR (%) p
G 1 768/1623 (47.3%) 43/222 (19.4%) 3.7 2.6-5.3 59.1 <0.001
G 2 511/833 (61.3) 43/152 (28.3%) 4.0 2.8-5.9 53.9 <0.001
Total 1279/2456 (52.1%) 86/374 (23.0%) 3.6 2.8-4.7 55.9 <0.001
Table 2. Incidences of PONV after antiemetic prophylaxis
PONV, postoperative nausea and vomiting; G 1, high-risk group; G 2, very high-risk group; OR, odds ratio; CI, confidence interval; RRR, relative risk
reduction.
Control group (n=2,465) Treatment group (n=374) OR 95% CI p
Nausea 1187/1456 (48.3%) 83/374 (22.2%) 3.3 2.5-4.2 <0.001
Vomiting 309/2456 (12.6%) 15/374 (4.0%) 3.4 2.0-5.8 <0.001
Table 3. Incidences of nausea and vomiting after antiemetic prophylaxis
OR, odds ratio; CI, confidence interval.Postoperative Nausea and Vomiting 881
factorial with the involvement of numerous receptor systems,
and there has been growing interests in using a combination
of antiemetics from different classes for PONV prophylaxis
(2, 9, 14). Many studies have already proven that antiemetic
interventions are effective in the prevention of PONV, and
furthermore, selective PONV prophylaxis in patients at
high risk for PONV is more cost-effective and associated
with a higher degree of patient satisfaction compared with
treatment of established symptoms (2, 15). Tramer (2) has
concluded in his review of strategies for PONV that there is
still no ‘gold standard’ antiemetic regimen for complete eradi-
cation of PONV but has proposed a rational three steps ap-
proach to minimize PONV: identification of patients at risk,
keeping the baseline risk low, and multimodal anti-emesis
for patients who are identified as high risk patients. In addi-
tion, a multidisciplinary panel of experts produced consen-
sus guidelines for managing PONV and developed algorithm
for most appropriate prophylaxis of PONV where surgical
patients are categorized into three classes (low, moderate,
and high) based on the patients’ risk factors (16). Similar to
this algorithm, we have arbitrarily classified patients into
four groups from our previous study based on the incidences
of PONV: low or mild (<20%), moderate (20-40%), high
(40-60%), and very high (>60%). 
In this study, we have selectively administered a combina-
tion of ondansetron and dexamethosone in high-risk and very
high-risk groups, and the incidences of PONV in these res-
pective groups were decreased by 29.1% and 27.9%. In addi-
tion, both high-risk and very high-risk groups showed a
similar degree of decreases in the relative risk, 59.0% vs.
53.8%. These results are similar to the Apfel’s (1) study in
which they have reported that the risk of PONV was reduc-
ed by about 26% each for ondansetron and dexamethasone
and the combination of these two drugs yielded greater than
50% reduction. However, based on the results of our study,
more relevant PONV management, supplementary to pro-
phylaxis, might be warranted in very high-risk patients
where PONV was still evident in approximately 30% despite
the prophylaxis. More recently, a multimodal management
strategy for the prevention of PONV has been studies exten-
sively and reported to be very effective (14, 16, 17). Habib
et al. (18) demonstrated that a multimodal PONV prophy-
laxis regimen incorporating total IV anesthesia (TIVA) with
propofol and a combination of ondansetron and droperidol is
more effective than a combination of these antiemetics in the
presence of an inhaled anesthetic. Their multimodal manage-
ment strategy was associated with a higher complete response
rate (no PONV and no rescue antiemetic) and greater patient
satisfaction. Therefore, in addition to the combination of
antiemetics acting at different receptor sites, the multifacto-
rial etiology of PONV might be better addressed by adopt-
ing a multimodal approach, especially in patients with very
high-risk factors for PONV.
The limitation of this study was that we selected the pati-
ents from our previous study as the control group rather than
using a placebo control group because these patients had com-
parable risk factors of PONV and matching characteristics
with the patients in the treatment group. Furthermore, it
was considered unethical to select the control group and leave
them unattended about the high risk of PONV. In addition,
same investigators following the same method performed both
studies.
In conclusion, the prophylactic administration of dexam-
ethasone and ondansetron reduced the incidence of PONV
in patients at both high-risk and very high-risk by 50%.
However, very high-risk patients still showed an around
30% incidence of PONV despite the prophylactic adminis-
tration of antiemetics. In this regard, future studies should be
directed on the multimodal approaches covering from pro-
phylactic antiemetics to TIVA to reduce the incidence of
PONV in very high-risk patients. 
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